Sanjaykumar Shah, MD
Family Medicine · Bossier City, LANPI 1740226505
Payments from drug & device makers
Across 636 payments — averaging $13.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- GSK$1K
- Lilly USA, LLC$809
- Novo Nordisk$601
- AstraZeneca$530
- Pfizer$491
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,33199%
- Education$771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 191 | $2,004 |
| GSK | 89 | $1,043 |
| Lilly USA, LLC | 61 | $809 |
| Novo Nordisk | 40 | $601 |
| AstraZeneca | 31 | $530 |
| Pfizer | 36 | $491 |
| Merck | 29 | $396 |
| Astellas Pharma US Inc | 23 | $333 |
| Boehringer Ingelheim | 20 | $286 |
| Amgen | 10 | $229 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $172 |
| Johnson & Johnson | 12 | $167 |
| Abbott | 8 | $144 |
| Daiichi Sankyo Inc. | 7 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $129 |
| Sanofi-aventis U.S. LLC | 9 | $124 |
| Phathom Pharmaceuticals, Inc. | 8 | $105 |
| Axsome Therapeutics, Inc. | 4 | $72 |
| Amarin Pharma, Inc. | 5 | $72 |
| Sumitomo Pharma America, Inc. | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $54 |
| Novartis | 3 | $50 |
| Exact Sciences | 3 | $49 |
| Itamar Medical Inc | 2 | $48 |
| Lundbeck LLC | 2 | $40 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $31 |
| Shield Therapeutics Inc | 2 | $30 |
| Corcept Therapeutics | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Bayer | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Recor Medical Inc | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $20 |
| Axonics, Inc. | 1 | $14 |
How this compares
$8,409 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 105 | $145,800 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $95,907 |
| JanuviaSitagliptin Phosphate | 67 | $78,737 |
| MounjaroTirzepatide | 59 | $67,959 |
| JardianceEmpagliflozin | 61 | $67,668 |
| EliquisApixaban | 56 | $63,482 |
| TrulicityDulaglutide | 53 | $56,587 |
| FarxigaDapagliflozin Propanediol | 48 | $43,009 |
| EntrestoSacubitril/Valsartan | 19 | $24,780 |
| LinzessLinaclotide | 34 | $24,275 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $18,385 |
| XareltoRivaroxaban | 18 | $18,199 |
| RybelsusSemaglutide | 17 | $17,602 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $14,383 |
| VoqueznaVonoprazan Fumarate | 15 | $10,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $601 | $163,402122 claims |
| Lilly USA, LLCMounjaro, Trulicity | $809 | $124,546112 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,043 | $114,292127 claims |
| MerckJanuvia | $396 | $78,73767 claims |
| Boehringer IngelheimJardiance, Jentadueto Xr | $286 | $74,01073 claims |
| PfizerEliquis, Paxlovid | $491 | $66,22182 claims |
| AstraZenecaFarxiga | $530 | $43,00948 claims |
| NovartisEntresto | $50 | $24,78019 claims |
| AbbVieLinzess | $2,004 | $24,27534 claims |
| Johnson & JohnsonXarelto | $167 | $18,19918 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $105 | $10,45215 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $56 | $6,92413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Bossier City
- Clint WilsonBossier City$208K
- Jason MilliganBossier City$15K
- Michael AngeloBossier City$15K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.